Literature DB >> 28597394

Invasive Candidiasis in Brescia, Italy: Analysis of Species Distribution and Antifungal Susceptibilities During Seven Years.

M A De Francesco1, G Piccinelli2, M Gelmi2, F Gargiulo2, G Ravizzola2, G Pinsi2, L Peroni2, C Bonfanti2, A Caruso2.   

Abstract

The aims of this study were to evaluate the epidemiology of nosocomial candidemia in a large teaching hospital in Brescia, Italy, and the in vitro antifungal susceptibility of isolates. We analyzed 196 isolates causing fungemia in patients admitted in our hospital, between January 2009 and December 2015. Strains were identified by VITEK 2 and MALDI-TOF MS. MICs were determined by Sensititre Yeast OneTM. The resistance was defined by using the revised CLSI breakpoints/epidemiological cutoff values to assign susceptibility or wild type to systemic antifungal agents. Most infections were caused by Candida albicans (60%), Candida parapsilosis (15%), Candida glabrata (12%) and Candida tropicalis (6%). The susceptibility rate for fluconazole was 96.5%. Non-Candida species isolates exhibited full susceptibilities to echinocandins according to CLSI breakpoints. Amphotericin B demonstrated excellent activity against all Candida species. Local epidemiological and antifungal susceptibility studies are necessary in order to improve empirical treatment guidelines.

Entities:  

Keywords:  Antifungal; Resistance; Susceptibility

Mesh:

Substances:

Year:  2017        PMID: 28597394     DOI: 10.1007/s11046-017-0155-3

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  29 in total

Review 1.  Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012.

Authors:  M A Pfaller; D J Diekema
Journal:  J Clin Microbiol       Date:  2012-06-27       Impact factor: 5.948

2.  European expert opinion on the management of invasive candidiasis in adults.

Authors:  B J Kullberg; P E Verweij; M Akova; M C Arendrup; J Bille; T Calandra; M Cuenca-Estrella; R Herbrecht; F Jacobs; M Kalin; C C Kibbler; O Lortholary; P Martino; J F Meis; P Muñoz; F C Odds; B E De Pauw; J H Rex; E Roilides; T R Rogers; M Ruhnke; A J Ullmann; Ö Uzun; K Vandewoude; J-L Vincent; J P Donnelly
Journal:  Clin Microbiol Infect       Date:  2011-09       Impact factor: 8.067

3.  The epidemiology of hematogenous candidiasis caused by different Candida species.

Authors:  D Abi-Said; E Anaissie; O Uzun; I Raad; H Pinzcowski; S Vartivarian
Journal:  Clin Infect Dis       Date:  1997-06       Impact factor: 9.079

4.  Invasive candidiasis in intensive care units in China: a multicentre prospective observational study.

Authors:  Fengmei Guo; Yi Yang; Yan Kang; Bin Zang; Wei Cui; Bingyu Qin; Yingzhi Qin; Qiang Fang; Tiehe Qin; Dongpo Jiang; Weiqin Li; Qin Gu; Hongsheng Zhao; Dawei Liu; Xiangdong Guan; Jianguo Li; Xiaochun Ma; Kaijiang Yu; Dechang Chan; Jing Yan; Yaoqing Tang; Wei Liu; Ruoyu Li; Haibo Qiu
Journal:  J Antimicrob Chemother       Date:  2013-03-29       Impact factor: 5.790

5.  Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among Candida bloodstream infection isolates: report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009).

Authors:  Michael A Pfaller; Gary J Moet; Shawn A Messer; Ronald N Jones; Mariana Castanheira
Journal:  J Clin Microbiol       Date:  2010-11-10       Impact factor: 5.948

6.  Epidemiology of Candida blood stream infections: experience of a tertiary care centre in North India.

Authors:  Jagdish Chander; Nidhi Singla; Shailpreet Kaur Sidhu; Satinder Gombar
Journal:  J Infect Dev Ctries       Date:  2013-09-16       Impact factor: 0.968

7.  A first Portuguese epidemiological survey of fungaemia in a university hospital.

Authors:  S Costa-de-Oliveira; C Pina-Vaz; D Mendonça; A Gonçalves Rodrigues
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-01-19       Impact factor: 3.267

8.  Molecular identification and antifungal susceptibility of yeast isolates causing fungemia collected in a population-based study in Spain in 2010 and 2011.

Authors:  Jesús Guinea; Óscar Zaragoza; Pilar Escribano; Estrella Martín-Mazuelos; Javier Pemán; Ferrán Sánchez-Reus; Manuel Cuenca-Estrella
Journal:  Antimicrob Agents Chemother       Date:  2013-12-23       Impact factor: 5.191

9.  Candidaemia with uncommon Candida species: predisposing factors, outcome, antifungal susceptibility, and implications for management.

Authors:  S C A Chen; D Marriott; E G Playford; Q Nguyen; D Ellis; W Meyer; T C Sorrell; M Slavin
Journal:  Clin Microbiol Infect       Date:  2009-07-15       Impact factor: 8.067

10.  Surveillance study of candidemia in cancer patients in North China.

Authors:  Ding Li; Wenfang Zhang; Shan Zheng; Zhenyi Ma; Peng Zhang; Zhe Liu
Journal:  Med Mycol       Date:  2012-10-10       Impact factor: 4.076

View more
  3 in total

1.  Evaluation of candidemia and antifungal consumption in a large tertiary care Italian hospital over a 12-year period.

Authors:  Jessica Mencarini; Elisabetta Mantengoli; Lorenzo Tofani; Eleonora Riccobono; Rossella Fornaini; Filippo Bartalesi; Giampaolo Corti; Alberto Farese; Patrizia Pecile; Luca Boni; Gian Maria Rossolini; Alessandro Bartoloni
Journal:  Infection       Date:  2018-04-13       Impact factor: 3.553

2.  Accuracy of matrix-assisted LASER desorption ionization-time of flight mass spectrometry for identification of Candida.

Authors:  Tian-Ao Xie; Ye-Ling Liu; Chuan Liang; Yuan-Yuan Huang; Jin-Wei Li; Zhong-Wei Li; Shu-Jin Fan; Jin-Tao Chen; Yong Xia; Xiao-Yan Li; Shi Ouyang; Tian-Xing Ji; Xu-Guang Guo
Journal:  Biosci Rep       Date:  2019-10-30       Impact factor: 3.840

3.  Multilocus Sequence Typing Reveals a New Cluster of Closely Related Candida tropicalis Genotypes in Italian Patients With Neurological Disorders.

Authors:  Fabio Scordino; Letterio Giuffrè; Giuseppina Barberi; Francesca Marino Merlo; Maria Grazia Orlando; Domenico Giosa; Orazio Romeo
Journal:  Front Microbiol       Date:  2018-04-06       Impact factor: 5.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.